

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ivan Michael Richards, et al :

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned
FILING DATE: Herewith : Group Art Unit: To Be Assigned
TITLE: Combination Therapies :

Mail Stop Patent Applications
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: April 13, 2004

Respectfully submitted,

Robert T. Ronau
Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-5910

EXPRESS MAIL NO. 20271824902US

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 1 of 2									ATTY. DOCKET NO. PC28025A			SERIAL NO. To Be Assigned		
									APPLICANT Ivan Michael Richards, et al.					
									FILING DATE Herewith			GROUP To Be Assigned		
U.S. PATENT DOCUMENTS														
EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5	0	9	6	8	9	0	17 March 92	Cross et al	514	422		
		5	9	7	3	1	8	2	26 Oct 99	Bakale et al	558	267		
		5	3	8	2	6	0	0	17 Jan 95	Jonsson et al	514	603		
	2001	0	0	5	1	7	2	7	13 Dec 01	Maligres et al	546	193		
		3	4	8	0	6	2	3	25 Nov 69	Consonni, et al	260	239.55		
		3	5	0	5	3	3	7	7 April 70	Zeile, et al	260	292		
		5	6	0	5	9	0	8	25 Feb 97	Merritt et al	514	305		
		5	9	9	8	4	0	4	7 Dec 99	Merritt et al	514	213		
		5	8	2	1	2	4	9	13 Oct 98	Wood et al	514	291		
		5	8	6	1	4	2	3	19 Jan 99	Caldwell et al	514	351		
		4	6	2	2	3	9	8	11 Nov 86	Laguzza	544	292		
		5	2	3	5	0	5	5	10 Aug 93	Stack et al	546	177		
		5	3	8	2	5	9	6	17 Jan 95	Sleevi et al	514	459		
		5	6	3	3	3	7	6	27 May 97	Thurkauf et al	544	360		
		5	6	7	4	9	0	9	7 Oct 97	Montanari et al	514	649		
		5	7	3	3	9	0	8	31 March 98	Peglion et al	514	229.5		
		5	7	4	7	5	1	3	5 May 98	Montanari et al	514	351		
		6	0	8	0	7	6	8	27 June 00	Montanari et al	514	357		
		5	7	5	0	5	5	6	12 May 98	Mewshaw et al	514	411		
		5	8	1	4	6	2	8	29 Sept 98	Fu et al	514	220		
		5	9	7	2	9	5	8	26 Oct 99	Nelson et al	514	307		
		3	9	2	9	7	6	8	30 Dec 75	Brattsand et al	260	239.55		
		4	4	7	2	3	9	3	18 Sept 84	Shapiro	424	243		
		3	9	0	4	6	1	7	9 Sept 75	Pelz et al	260	243 R		
		4	1	1	8	3	9	4	3 Oct 78	Demerson et al	260	326.28		
		3	8	9	1	6	4	4	24 June 75	White	260	251 A		
		3	9	5	7	8	1	9	18 May 76	White	260	326.15		
		3	9	7	6	6	4	5	24 Aug 76	White	260	251 A		
		4	8	8	0	8	0	1	14 Nov 89	Kitchin et al	514	215		
		3	5	7	7	4	2	4	4 May 71	Ehrhart, et al	260	287		
		3	7	1	2	8	9	0	23 Jan 73	Lee, et al	260	247.7 C		
		4	3	1	4	0	8	1	2 Feb 82	Molloy et al	564	347		
		5	0	2	3	2	6	9	11 June 91	Robertson et al	514	438		
		4	5	3	5	1	8	6	13 Aug 85	Husbands et al	564	336		
		4	2	2	9	4	4	9	21 Oct 80	Melloni et al	424	248.58		
		4	4	7	8	8	3	6	23 Oct 84	Mouzin et al	424	248.54		
		4	2	0	1	7	8	3	6 May 80	Briet et al	424	256		
		3	9	9	5	0	5	2	30 Nov 76	Jirkovsky et al	424	275		
		6	3	3	3	3	5	4	25 Dec 01	Schudt	514	573		
		5	0	7	1	8	6	4	10 Dec 91	Rendenback- Mueller et al	514	370		
		6	0	2	5	3	5	6	15 Feb 00	Peglion et al	514	229.8		

EXPRESS MAIL NO. 20018240205

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 2 of 2								ATTY. DOCKET NO. PC28025A				SERIAL NO. To Be Assigned			
								APPLICANT Ivan Michael Richards, et al.							
								FILING DATE Herewith				GROUP To Be Assigned			
		4	3	3	5	1	2	1	15 June 82	Phillipps et al	424	241			
		6	3	3	1	5	4	3	18 Dec 01	Garvey et al	514	250			
FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
	WO	9	8	2	9	4	0	2	9 July 98	PCT	C07D	311/20	YES	NO	
	EP	0	8	0	1	0	6	7	15 Oct 97	EPO	C07D	453/02			
	WO	9	7	0	8	1	4	6	6 March 97	PCT	C07D	213/66			
	WO	9	9	6	7	2	6	3	29 Dec 99	PCT	C07H	19/16			
	WO	0	0	5	1	9	7	0	8 Sept 00	PCT	C07C	233/65			
	WO	02	0	9	4	2	7	3	28 Nov 2002	PCT	A61K	31/52			
	WO	02	0	9	6	4	6	2	5 Dec 02	PCT	A61K	45/06			
	WO	9	5	3	3	7	2	9	14 Dec 95	PCT	C07D	233/32			
	WO	9	6	0	4	9	1	0	22 Feb 96	PCT	A61K	31/445			
	WO	9	8	0	8	8	1	7	5 March 98	PCT	C07D	209/08			
	WO	9	8	0	8	8	4	3	5 March 98	PCT	C07D	409/12			
	WO	9	8	3	5	9	4	5	20 Aug 98	PCT	C07D	235/06			
	WO	9	8	3	5	9	4	8	20 Aug 98	PCT	C07D	241/44			
	WO	9	8	3	8	1	5	5	3 Sept 98	PCT	C07C	215/64			
	WO	0	0	1	6	7	7	7	30 March 00	PCT	A61K	31/505			
	WO	0	2	9	6	4	2	2	5 Dec 02	PCT	A61K	31/46			
	EP	0	8	7	5	5	1	2	4 Nov 98	EPO	C07D	403/06			
	WO	9	2	1	3	8	7	2	20 Aug 92	PCT	C07J	71/00			
	EP	0	0	5	7	4	0	1	11 Aug 82	EPO	C07J	17/00			
	WO	02	0	9	6	4	2	3	5 Dec 2002	PCT	A61K	31/46			
	WO	02	0	9	6	4	6	3	5 Dec 2002	PCT	A61K	45/06			
	WO	0	1	7	8	7	4	5	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	7	8	7	4	4	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	7	8	7	3	7	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	7	8	7	4	3	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	7	8	7	4	1	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	7	8	7	3	9	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	7	8	7	3	6	25 Oct 2001	PCT	A61K	31/575			
	WO	0	1	6	2	2	3	6	30 Aug 2001	PCT	A61K	31/00			
	WO	0	1	1	2	1	6	7	22 Feb 2001	PCT	A61K	31/00			
	WO	0	1	8	2	9	3	1	8 Nov 2001	PCT	A61K	31/52			
	WO	9	9	6	5	4	6	4	23 Dec 99	PCT	A61K	31/135			
	WO	9	3	2	4	4	7	3	9 Dec 93	PCT	C07D	277/68			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
		Int. J. Pharm, 33, 201-217, 1986													
		N. Watson et al., Eur. J. Pharmacol, 285(2), pgs 135-142, 1995													
		Visser et al., Biochem. Pharmacol, 60, 993-999, 2000													
		Martin et al., Drug Dev. Res., 40, 313-324, 1997													
		Keeling et al., Bioorg. Med. Chem. Lett. 10, 403-406, 2000													
		Kull et al., Biochem. Pharmacol, 57, 65-75, 1999													
		Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 832-834, Joel G. Hardman et al eds., 9 th ed. 1996													
EXAMINER															
DATE CONSIDERED															